We further found that primary leukemia cells use Ppm1d to attenuate the cytotoxic effects of clinically used therapies and that genetic loss or pharmacologic inhibition of Ppm1d sensitizes mouse and human leukemia cells to these agents in vitro and in vivo. This evidence concerns the gene PPM1D and leukemia.